Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar: financing pressure. About 2.8 months of cash at its recent burn rate (Sep 30, 2026 balance sheet), an at-the-market (ATM) program filed Aug 21, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 months of cash or less, 51% sold new shares within three months and 73% were lower 60 trading days later (median -24%). How we know
$7.3MCash on Hand
2.8mo Cash Runway
Follow MBRX by emailGet an email when MBRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MBRX, unsubscribe in one click. Privacy
📣 What MBRX Says Is Next
first quarter of 2027 · “The Company remains on track for a comprehensive data readout in the first quarter of 2027.”
Company press release, Nov 16, 2026 · SEC filing
first half of 2027 · “These data are expected to support selection of the optimal Annamycin dose for advancement into Part B, which is currently planned to begin in the first half of 2027.”
Company press release, Nov 16, 2026 · SEC filing
first quarter of 2027 · “The Company remains on track to report comprehensive Part A data in the first quarter of 2027.”
Company press release, Nov 16, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Earnings Reported Q3 2026 results: R&D expenses about $4.5 million versus $3.7 million a year earlier, G&A about $2.1 million, and a net loss of about $6.5 million versus $25.4 million. Completed treatment of all 90 Part A patients in the MIRACLE trial, with the comprehensive data readout on track for Q1 2027. Form 8-K · SEC filing · Press release
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Granted an Australian patent (No. 2020303572), co-owned with The Board of Regents of The University of Texas System, covering preparation of preliposomal Annamycin lyophilizate. The company says this strengthens its formulation IP, and its patent portfolio spans multiple other jurisdictions. Form 8-K · SEC filing · Press release
Nov 10, 2026 ·
Clinical trial Moleculin reported preclinical data showing its drug Annamycin combined with PD-1 checkpoint blockade extended survival in pancreatic cancer mouse models beyond either agent alone, with results to be presented at a Tampa symposium on November 10. Form 8-K · SEC filing · Press release
Nov 4, 2026 ·
Clinical trial Moleculin said an abstract on Annamycin data from the first interim analysis of its pivotal MB-108 trial was accepted for an ASH poster on December 12-15, 2026. Among the first 45 randomized patients, complete remission rates were 43% and 36% in the Annamycin arms versus 12% for placebo. Form 8-K · SEC filing · Press release
Oct 30, 2026 ·
Clinical trial Moleculin completed dosing in Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin with cytarabine in relapsed or refractory AML. Comprehensive Part A data remain on track for Q1 2027, covering 90 patients. Form 8-K · SEC filing · Press release
Oct 20, 2026 ·
Listing Moleculin's board effected a 1-for-20 reverse stock split, effective 12:01 a.m. ET on October 20, 2026, with shares trading on Nasdaq under MBRX and new CUSIP 60855D507. Outstanding shares fall from about 20.9 million to about 1.05 million. Form 8-K · SEC filing · Press release
Oct 16, 2026 ·
Moleculin Biotech furnished an investor presentation dated October 16, 2026, posted on its website as Exhibit 99.1. The filing text itself contains no new results, numbers or deal terms. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Aug 2029 · Phase 2/3 · Recruiting · L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not MBRX's own candidates): Cytarabine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
MBRX holds $7.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $7.8M/quarter from operations,
an estimated runway of 2.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:80 · High
Cash runway 3 months +40
ATM program on file since Aug 2026 +15
Shelf registration (S-3, Jun 2024) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt regarding the Company's ability to continue as a going concern.10-Q, Nov 2026
Share count 1,061,533 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full MBRX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MBRX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.